Progyny shares surge 10.77% premarket as analysts raise fair value to $29.40, citing stronger utilization and IVF growth.

Progyny (PGNY) surged 10.77% in premarket trading, driven by recent analyst upgrades and positive earnings momentum. Analysts raised the stock’s fair value to $29.40 from $28.25, citing stronger utilization trends and expanding IVF coverage. Concurrently, Progyny’s Q2 2025 results highlighted record revenue and strategic partnerships, with Cantor Fitzgerald and Truist Financial raising price targets. A “Moderate Buy” rating from brokerages and institutional buying activity further reinforced optimism. While mixed sentiment from earnings multiple concerns and occasional selling by shareholders existed, the immediate catalyst appears to be the upward revision in fair value estimates and robust quarterly performance, aligning with the sharp premarket rally.